Food Allergy

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.

This analysis suggests that the financial burden of oral food challenges may be offset slightly through the use of FPIES.

These data, to be presented at AAAAI, indicate that following 12 and 24 months of immunotherapy with BMOIT, desensitization to milk products can be observed among patients.

The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.

These data also showed that basophil activation test can be a particularly precise biomarker of allergy compared to tolerance among children who are egg-allergic children.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

The decision by the FDA is a step closer to omalizumab’s potential approval, making it the potential first medicine to reduce reactions to many different food allergens after accidental exposure.

During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.

In this interview segment, Dr. Kim described some of the background and importance of the Harmony study data presented at ACAAI for patients with food allergy.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.

The agency’s guideline updates were announced, with the overall goal being to help food facilities in their adherence to current good manufacturing practices.

This research shows that a basophil activation test can support decision-making by clinicians when re-introduction of baked eggs in patients with allergies is a treatment being considered.

This analysis on a larger study population led to results which add useful data to the growing literature on sesame thresholds and may even help to assess sesame safe doses used in risk management.

The new research in this study indicates that both types of food challenges may be equally useful when conducted by trained staff who use strict objective stop criteria.

This expanded upon the limited data available on risks of precautionary allergen label food introduction for those with allergies, the results of which suggest new possibilities for future allergy management.

This interview segment with Dr. Kidon featured a discussion about her views on current research in the immunotherapy and food allergy space, as well as her views on the future.

Dr. Kidon spoke in this interview segment regarding a recent immunotherapy product she and her team have been focused on for patients with peanut allergies.

This interview with Dr. Kidon featured a discussion regarding Kidon’s current peanut allergy research and views on recent developments in the field.

This new research is the first to examine the use of the iMAP milk ladder in primary care settings for younger patients with IgE-mediated cow’s milk protein allergy.

These new findings may lead to a more accessible and rigorous approach to diagnosis, with a possibility of reduction of over-diagnosis.

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.